06.05.14
Dehaier Medical Systems Ltd., an emerging medical technology company focused on sleep respiratory products in China, has received approval from the China Food and Drug Administration (CFDA) for its Morpheus Ox software.
The Morpheus Ox system is a portable home sleep diagnostic and monitoring solution that works by collecting and recording the physiological data from patients who wear the watch-sized device at home. The automatic sleep scoring software makes a sleep diagnosis using measures such as the Apnea Hypopnea Index sleep/wake time and Cheyne-Stokes breathing patterns. According to the company, the new generation Morpheus Ox is a comprehensive platform that manages a cost-effective sleep services operation, including patient electronic medical records, cardiac and sleep diagnostics results, as well as complete workflow management. The web-based automatic scoring and data management is meant to increase operational efficiency.
Dehaier Medical applied to the CFDA to register the Morpheus Ox in July 2013. With completion of this registration, the company has collected all certifications for four key components of Dehaier’s Sleep Respiratory Solutions in order to establish a comprehensive product line for obstructive sleep apnea: the second generation DHR998 Sleep Diagnostic Device; photoplethysmography (PPG) sensor; sleep diagnostic software; and continuous positive airway pressure ventilator. Dehaier’s Morpheus Ox products assist with the diagnosis of sleep apnea, provide treatment options to apnea patients and allow post-treatment evaluation services to pinpoint further opportunities for improvement.
“We are confident that China’s sleep respiratory market, which is still at an early stage of development, has tremendous growth potential and that our products position us well to increase market share,” said Chairman and CEO Ping Chen. “Our comprehensive line of products focused on disease diagnosis, treatment and curative effect evaluation provide a one-stop solution to meet market demand. After the receipt of the fourth registration certificate for our Morpheus Ox product line, we are ready to launch the solution for sale. We showcased the Morpheus Ox System and workstation at the 2014 Third Annual Jiangxi Sleep Medicine Seminar from May 30 to 31, 2014. Based on our marketing campaign during the past couple months, we are excited to see strong interest from a variety of hospitals and physical examination centers. We are beginning to further our marketing and sales activities for our sleep respiratory products nationwide, and we expect our sleep respiratory business will grow through the rest of 2014 as we move toward mobile health care and telemedicine.”
The Morpheus Ox system is a portable home sleep diagnostic and monitoring solution that works by collecting and recording the physiological data from patients who wear the watch-sized device at home. The automatic sleep scoring software makes a sleep diagnosis using measures such as the Apnea Hypopnea Index sleep/wake time and Cheyne-Stokes breathing patterns. According to the company, the new generation Morpheus Ox is a comprehensive platform that manages a cost-effective sleep services operation, including patient electronic medical records, cardiac and sleep diagnostics results, as well as complete workflow management. The web-based automatic scoring and data management is meant to increase operational efficiency.
Dehaier Medical applied to the CFDA to register the Morpheus Ox in July 2013. With completion of this registration, the company has collected all certifications for four key components of Dehaier’s Sleep Respiratory Solutions in order to establish a comprehensive product line for obstructive sleep apnea: the second generation DHR998 Sleep Diagnostic Device; photoplethysmography (PPG) sensor; sleep diagnostic software; and continuous positive airway pressure ventilator. Dehaier’s Morpheus Ox products assist with the diagnosis of sleep apnea, provide treatment options to apnea patients and allow post-treatment evaluation services to pinpoint further opportunities for improvement.
“We are confident that China’s sleep respiratory market, which is still at an early stage of development, has tremendous growth potential and that our products position us well to increase market share,” said Chairman and CEO Ping Chen. “Our comprehensive line of products focused on disease diagnosis, treatment and curative effect evaluation provide a one-stop solution to meet market demand. After the receipt of the fourth registration certificate for our Morpheus Ox product line, we are ready to launch the solution for sale. We showcased the Morpheus Ox System and workstation at the 2014 Third Annual Jiangxi Sleep Medicine Seminar from May 30 to 31, 2014. Based on our marketing campaign during the past couple months, we are excited to see strong interest from a variety of hospitals and physical examination centers. We are beginning to further our marketing and sales activities for our sleep respiratory products nationwide, and we expect our sleep respiratory business will grow through the rest of 2014 as we move toward mobile health care and telemedicine.”